VB 201

Drug Profile

VB 201

Alternative Names: CI-201; VB-201

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VBL Therapeutics
  • Class Anti-inflammatories; Phospholipids; Small molecules
  • Mechanism of Action CD14 antigen inhibitors; Cell movement inhibitors; Interleukin 12 subunit p40 inhibitors; Phospholipid modulators; Toll like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis
  • Preclinical Hepatic fibrosis; Non-alcoholic fatty liver disease
  • No development reported Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 03 Apr 2017 Pharmacodynamics data from a post-hoc analysis of phase II trials released by VBL Therapeutics
  • 09 Jan 2017 VB 201 is available for licensing as of 09 Jan 2017 http://www.vblrx.com/
  • 30 Jun 2015 VB 201 is still in phase II trials for Atherosclerosis in USA, Germany and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top